NCT00157950View on ClinicalTrials.gov

Human Papillomavirus (HPV) Registration Study (Gardasil)(V501-023)(COMPLETED)

PHASE3CompletedINTERVENTIONAL
Enrollment

176

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

June 30, 2006

Study Completion Date

June 30, 2006

Conditions
Papillomavirus Infections
Interventions
BIOLOGICAL

Gardasil™

Gardasil™ 3 dose regimen (Day 1, Month 2 and Month 6)

BIOLOGICAL

Placebo

Gardasil™ matching placebo 3 dose regimen (Day 1, Month 2 and Month 6)

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00157950 - Human Papillomavirus (HPV) Registration Study (Gardasil)(V501-023)(COMPLETED) | Biotech Hunter | Biotech Hunter